Reports
Global Hidradenitis Suppurativa Treatment Market Growth, Analysis, Trends, Forecast: By Skin Condition: Pimples, Folliculitis, Deep-Acne, Choroid Plexus Papilloma/Carcinoma, Boils, Others; By Hurly Stages: Hurly Stages I, Others; By Treatment Method; By End User; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Hidradenitis Suppurativa Treatment Market Outlook
The global hidradenitis suppurativa treatment market attained a value of USD 800 million in 2022. The market is expected to grow at a CAGR of 4.20% during the forecast period of 2023-2031, driven by the rising prevalence and the increasing availability of treatment facilities.
Hidradenitis Suppurativa Treatment Market: Introduction and Insights
Hidradenitis suppurativa (HS) is an autoinflammatory and non-contagious skin condition which targets the hair follicles, leading to recurring abscesses in sweaty areas of the body, which are painful as well. The body parts that can be affected include groin, axillary, perineal, perianal, and inframammary locations. While there is no cure for the condition yet, but the treatment can help relieve the symptoms and prevent further progression of the condition.
Hidradenitis suppurativa (HS), also known as acne inversa, is often diagnosed at a later stage because it is mostly confused with skin infection or severe acne. There is no known diagnostic method to detect this condition, so the patient becomes completely dependent on the dermatologist to diagnose the condition based on the medical history of the patient, symptoms, and the appearance of these lesions. HS also leads to other associated conditions like severe pain, drainage, sensitive skin, odour, and deep scarring. The most common condition where the doctor suggests the possibility of this condition is when the painful lesions are filled with pus and drainage.
It is a sensitive condition which requires proper treatment method customised especially for the patient based on their individual symptoms. The appearance of HS can differ from person to person. HS leads to the formation of skin growths like nodules, abscesses, or sinus tracts.
Hidradenitis Suppurativa Treatment Market Segmentations
Market Breakup by Skin Condition
- Pimples
- Folliculitis
- Bacterial Folliculiti
- Hot Tub Folliculitis (Pseudomonas Folliculitis)
- Barber's Itch (Pseudofolliculitis Barbae)
- Pityrosporum Folliculitis
- Others
- Deep-Acne
- Cysts
- Blackheads
- Others
- Choroid Plexus Papilloma/Carcinoma
- Boils
- Furuncle Or Carbuncle
- Cystic Acne
- Pilondial Cyst
- Others
- Others
Market Breakup by Hurly Stages
- Hurly Stages I
- Hurly Stages II
- Hurly Stages III
Market Breakup by Treatment Method
- Drugs
- NSAIDs
- Antibiotics
- Corticosteroid
- Oral Retinoids
- Topical Resorcinol
- Hormone Therapy
- Surgery
- Punch Debridement
- Surgical Removal
- Incision and Drainage
- Issue-Sparing Excision with Electrosurgery
- Laser Treatment
- Photodynamic Therapy (PDT)
- Others
Market Breakup by End User
- Hospitals
- Dermatology Clinics
- Medical Research Centres
- Academic Institutes
- Others
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Epidemiology
The prevalence of the disease is low, possibly due to the lack of diagnostic facilities for this condition. This can also be attributed to the under-reporting and misdiagnosis of the condition owing to the lack of awareness about the condition. The disease is most likely to occur between the age of puberty to the age of around forty years, especially between the age of 21 to 29 years. Women are more vulnerable to this condition than men, there is a ratio of 3:1 between women and men.
Treatments and Therapies Used in the Global Hidradenitis Suppurativa Treatment Market
There are no cures for the disease yet, but the treatments can help in reducing inflammation and pain and heal the wounds. The available treatments can help in preventing the progression of the condition.
The treatments currently available in the market include the following:
Skin Care- The first and foremost treatment that the dermatologist opts for the condition in the initial stages is skin care. Regular products available in the market might not help or even aggravate the condition even further. The dermatologist can make a skin care plan customized according to the condition and suggest products that can help in relieving inflammation and pain and these products are also useful in reducing the scarring. The most common addition to the skin care routine is a benzol peroxide facewash, followed by a gentle hydrating moisturizer, and over the top treatment gel. While other treatments might go on for some time, this is something that the patient has to follow throughout the condition to avoid recurrence of the condition.
Drugs or Medications- These drugs can be for be for oral consumption or topical application, depending on the severity of the HS. If the HS is mild and limit to a certain body part, then only topical medication is prescribed. If it is advanced and has spread throughout the body, then a combination of topical and oral medicines is used over a period of time. The most prominent drugs include NSAIDs, antibiotics, oral retinoids, corticosteroid, and hormone therapy, among others. These drugs must be used for the prescribed period of time only and not more due to their high potency.
Surgery- Severe HS is treated with punch debridement, surgical removal, incision and drainage, and issue-sparing excision with electrosurgery.
Other treatment options include in-clinic treatments like corticosteroid injection, laser surgery, botulinum toxin, incision and drainage, wide excision, deroofing, wound and pain care treatments, among others.
Competitive Landscape of the Hidradenitis Suppurativa Treatment Market
The report gives an in-depth analysis of the key players involved in the hidradenitis suppurativa treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- USB Biopharma
- Novartis International AG
- InflaRx GmbH
- Janssen Biotech, Inc.
- AbbVie Inc.
- Celgene Corp.
- ChemoCentryx Inc.
- Incyte Corporation
- Pfizer Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Skin Condition |
|
| Breakup by Hurly Stages |
|
| Breakup by Treatment Method |
|
| Breakup by End User |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Hidradenitis Suppurativa Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global Hidradenitis Suppurativa Treatment Market
8.1 Global Hidradenitis Suppurativa Treatment Market Overview
8.2 Global Hidradenitis Suppurativa Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Hidradenitis Suppurativa Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Hidradenitis Suppurativa Treatment Market Forecast Value (2023-2031)
8.3 Global Hidradenitis Suppurativa Treatment Market by Skin Condition
8.3.1 Market Overview
8.3.1.1 Pimples
8.3.1.2 Folliculitis
8.3.1.2.1 Bacterial Folliculitis
8.3.1.2.2 Hot Tub Folliculitis (Pseudomonas Folliculitis)
8.3.1.2.3 Barber's Itch (Pseudofolliculitis Barbae)
8.3.1.2.4 Pityrosporum Folliculitis
8.3.1.2.5 Others
8.3.1.3 Deep-Acne
8.3.1.3.1 Cysts
8.3.1.3.2 Blackheads
8.3.1.3.3 Others
8.3.1.4 Choroid Plexus Papilloma/Carcinoma
8.3.1.5 Boils
8.3.1.5.1 Furuncle Or Carbuncle
8.3.1.5.2 Cystic Acne
8.3.1.5.3 Pilondial Cyst
8.3.1.5.4 Others
8.3.1.6 Others
8.4 Global Hidradenitis Suppurativa Treatment Market by Hurly Stages
8.4.1 Market Overview
8.4.1.1 Hurly Stages I
8.4.1.2 Hurly Stages II
8.4.1.3 Hurly Stages III
8.5 Global Hidradenitis Suppurativa Treatment Market by Treatment Method
8.5.1 Market Overview
8.5.1.1 Drugs
8.5.1.1.1 NSAIDs
8.5.1.1.2 Antibiotics
8.5.1.1.3 Corticosteroid
8.5.1.1.4 Oral Retinoids
8.5.1.1.5 Topical Resorcinol
8.5.1.1.6 Hormone Therapy
8.5.1.2 Surgery
8.5.1.2.1 Punch Debridement
8.5.1.2.2 Surgical Removal
8.5.1.2.3 Incision and Drainage
8.5.1.2.4 Issue- Sparing Excision with Electrosurgery
8.5.1.3 Laser Treatment
8.5.1.4 Photodynamic Therapy (PDT)
8.5.1.5 Others
8.6 Global Hidradenitis Suppurativa Treatment Market by End User
8.6.1 Market Overview
8.6.1.1 Hospitals
8.6.1.2 Dermatology Clinics
8.6.1.3 Medical Research Centres
8.6.1.4 Academic Institutes
8.6.1.5 Others
8.7 Global Hidradenitis Suppurativa Treatment Market by Treatment Channel
8.7.1 Public
8.7.2 Private
8.8 Global Hidradenitis Suppurativa Treatment Market by Region
8.8.1 Market Overview
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 North America Hidradenitis Suppurativa Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Hidradenitis Suppurativa Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Hidradenitis Suppurativa Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Hidradenitis Suppurativa Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Hidradenitis Suppurativa Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Hidradenitis Suppurativa Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 USB Biopharma
15.1.1 Product Portfolio
15.1.2 Demographic Reach and Achievements
15.1.3 Mergers and Acquisitions
15.1.4 Certifications
15.2 Novartis International AG
15.2.1 Product Portfolio
15.2.2 Demographic Reach and Achievements
15.2.3 Mergers and Acquisitions
15.2.4 Certifications
15.3 InflaRx GmbH
15.3.1 Product Portfolio
15.3.2 Demographic Reach and Achievements
15.3.3 Mergers and Acquisitions
15.3.4 Certifications
15.4 Janssen Biotech Inc.
15.4.1 Product Portfolio
15.4.2 Demographic Reach and Achievements
15.4.3 Mergers and Acquisitions
15.4.4 Certifications
15.5 AbbVie Inc.
15.5.1 Product Portfolio
15.5.2 Demographic Reach and Achievements
15.5.3 Mergers and Acquisitions
15.5.4 Certifications
15.6 Celgene Corp.
15.6.1 Product Portfolio
15.6.2 Demographic Reach and Achievements
15.6.3 Mergers and Acquisitions
15.6.4 Certifications
15.7 ChemoCentryx Inc.
15.7.1 Product Portfolio
15.7.2 Demographic Reach and Achievements
15.7.3 Mergers and Acquisitions
15.7.4 Certifications
15.8 Incyte Corporation
15.8.1 Product Portfolio
15.8.2 Demographic Reach and Achievements
15.8.3 Mergers and Acquisitions
15.8.4 Certifications
15.9 Pfizer Inc.
15.9.1 Product Portfolio
15.9.2 Demographic Reach and Achievements
15.9.3 Mergers and Acquisitions
15.9.4 Certifications
15.10 Abbott
15.10.1 Product Portfolio
15.10.2 Demographic Reach and Achievements
15.10.3 Mergers and Acquisitions
15.10.4 Certifications
16 Global Hidradenitis Suppurativa Treatment Market-Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The hidradenitis suppurativa treatment market attained a value of nearly USD 800 million in 2022.
The market is projected to grow at a CAGR of 4.20% during the forecast period of 2023-2031.
The growth of the market is driven by factors like rising awareness about the disease.
The rising awareness about the available treatments and the rising accessibility to dermatologists are among the key trends.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Different skin conditions can be categorised into pimples, folliculitis, deep-acne, choroid plexus papilloma/carcinoma, and boils, among others.
The hurly stages of the disease include stage I, II, and III.
Different treatment methods include drugs, surgery, laser treatment, and photodynamic therapy (PDT), among others.
The end-use sectors include hospitals, dermatology clinics, medical research centres, and academic institutes, among others.
The treatment channels in the market include public and private, among others.
The key players in the market include Novartis International AG, InflaRx GmbH, Janssen Biotech, Inc., AbbVie Inc., Celgene Corp., ChemoCentryx Inc., Incyte Corporation, Pfizer Inc., and USB Biopharma.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER